Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
Article
[키워드] analyzed
anti-S
antibody
Antibody titer
B.1.1.7
B.1.351 variant
BNT162b2
BNT162b2 vaccine
COVID-19
COVID-19 vaccine
D614G
decrease
detectable
experiments
first dose
hcp
Healthcare professional
humoral
immune response
induce
Infection
Kinetics
magnitude
Month
mRNA vaccine
multicenter
neutralization
neutralization activity
Prevent
receiving
Roche anti-SARS-CoV-2-S
SARS-CoV-2
SARS-CoV-2 infections
serological test
seropositive individual
serum antibody
severe COVID-19
severe symptoms
T 3
the antibody response
the receptor-binding domain
the SARS-CoV-2
the spike protein
the vaccine
threshold
titer
vaccination
Vaccination strategies
was tested
were measured
[DOI] 10.3390/vaccines9111357 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/vaccines9111357 PMC 바로가기 [Article Type] Article